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Abstract Common genetic variations in the gene encoding
transcription factor 7-like 2 (TCF7L2) reveal the strongest
association with type 2-diabetes known to date. These lead
to impaired insulin production and output, but the mecha-
nisms of disease remain incompletely known. In this issue
of Diabetologia, two publications provide new insights into
TCF7L2-dependent diabetes.
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The heterogeneity of type 2 diabetes, taken together with the
number of genetic risk variants involved in the pathogenesis
of the disease, calls for reflection when singling out the most
important diabetes gene. Even so, few would object to the
transcription factor TCF7L2 being given that status. After
the initial discovery of the strong association of genetic
variation in TCF7L2 with type 2 diabetes in 2006 [1], the
subsequent genome-wide association studies (GWASs) for
type 2 diabetes identified the single-nucleotide polymor-
phism (SNP) rs7903146 in intron 4 as the genetic variation
most strongly associated with disease in European–Ameri-
can populations [2–5]. The importance of genetic variation
in TCF7L2 for type 2 diabetes has been replicated in
numerous studies in populations of diverse ethical back-
grounds, although the exact location of the genetic variation
associated with the disease is different in cohorts of Asian
descent [6].
The general lesson learnt from the GWASs is that the vast
majority of genetic risk variants associated with type 2
diabetes reduce the capacity for insulin secretion. Likewise,
the clinical phenotype of TCF7L2-related type 2 diabetes is
that of insulin deficiency. As for any genetic risk variant that
associates with insulin deficiency, it may result from cellular
factors that reduce beta cell mass and/or lower insulin output
by impairing beta cell function. At present, we lack methods
to unequivocally determine the predominant mechanism of
reduced insulin production at different stages of disease. Be
that as it may, the genetic discoveries have prompted intense
activity in the area of islet biology. Despite the collective
efforts by many different groups we are still far from having
a unifying view on which functions transcription factor
7-like 2 (TCF7L2) protein fulfils under normal conditions,
or how these fail during the development and progression of
type 2 diabetes. The report by da Silva and colleagues in this
issue of Diabetologia [7] adds another important facet to the
evolving understanding of this transcription factor in glu-
cose homeostasis. The present study clarifies several of the
outstanding issues concerning the fundamental actions of
TCF7L2 and its products on beta cell performance.
TCF7L2 is part of a transcriptional complex with broad
target specificity. Furthermore, transcription of target genes
may either be suppressed or activated depending on cellular
conditions. Compounding this, TCF7L2 is subject to tissue-
and perhaps context-dependent alternative splicing. This is
likely to affect target gene specificity, as well as the degree
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of activation vs repression of target gene expression. The
authors and the Maedler laboratory have previously reported
that silencing small interfering (si)RNAs expected to pre-
vent formation of all TCF7L2 isoforms affects the capacity
for insulin secretion in rodents [8, 9]. Collectively, these
studies point to a role of the transcription factor in the later
stages of the insulin stimulus secretion coupling. This is
associated not only with downregulation of several
exocytosis-regulating proteins, but also with an increased
rate of apoptosis. The latter effect was demonstrated by the
Hansson group to involve the tumour suppressor protein
p53 pathway [10], and it suggests that TCF7L2 may play
a role in maintaining an appropriate beta cell mass.
Furthermore, patients with the risk T allele in rs7903146
display a clearly deteriorated incretin effect (i.e. the normal
amplification of insulin output in response to a glucose load
when given orally instead of intravenously is compromised)
[11]. In this context, it is of particular interest that several
lines of evidence suggest cross-talk between TCF7L2 and
the incretin hormone glucagon-like peptide 1 (GLP1). Ini-
tially, the proglucagon gene was suggested as a potential
target of TCF7L2 and impaired GLP1 production in the
intestinal L cells was, for a while, the prime suspect in
TCF7L2-dependent diabetes. This hypothesis was later
abandoned, but there are repeated reports that the levels of
the GLP1 receptor (GLP1r) transcript are suppressed when
TCF7L2 expression is silenced [8, 12, 13]. GLP1 amplifies
glucose-induced insulin secretion and maintains beta cell
mass by suppressing apoptosis and stimulating proliferation.
In fact, the latter effect has been specifically demonstrated to
depend on TCF7L2 [14], offering a potentially specific
mechanism for how TCF7L2 may affect beta cell mass.
TCF7L2 is widely expressed, with particularly high lev-
els in, for example, certain regions of the brain; in contrast,
expression in the pancreas is relatively modest. Although
clinical data without doubt favour a pancreatic origin of
TCF7L2-dependent diabetes, it is impossible to unequivo-
cally rule out that metabolically active tissues other than the
pancreas are the relevant ones for diabetes pathology. Here,
mouse models may offer important keys to a better under-
standing and also allow for direct studies of beta cell mass.
Mice with global ablation of Tcf7l2 have previously been
generated [15]. However, homozygous Tcf7l2-null mice die
shortly after birth, and study of heterozygous mice with one
intact allele cannot help to establish the specific role of the
pancreas in Tcf7l2-dependent pathology.
To overcome these shortcomings, the authors generated a
pancreas-specific Tcf7l2-null mouse strain (pTcf7l2) by
crossing pTcf7l2-flox mice with mice expressing Cre recom-
binase under the control of the pancreatic and duodenal
homeobox 1 (PDX1). Interestingly, these mice had impaired
oral glucose tolerance from week 12, and later, at week 20,
also developed intolerance to intravenous glucose loads.
Moreover, glucose- and GLP1-stimulated insulin secretion
in islets from pTcf7l2 mice was markedly reduced. Interest-
ingly, this coincided with reduced GLP1-receptor (Glp1r)
and insulin (Ins2) gene expression. Finally, the authors
demonstrated that pTcf7l2 mice maintained on a high-fat
diet failed to expand the beta cell volume to the same degree
as their control littermates. These results provide direct
evidence for the importance of pancreatic TCF7L2 for main-
taining glucose tolerance. They also provide strong evidence
for the involvement of GLP1 signalling in that respect.
This work clarifies the physiological role of pancreatic
TCF7L2 and provides a solid platform for further endeav-
ours to understand how genetic variation in the human
TCF7L2 gene generates the increased risk of type 2 diabe-
tes. Intriguingly, another report in the current issue of Dia-
betologia, by Le Bacquer and colleagues [16], investigates
the functional and morphological consequences of
rs7903146 in human islets. Homozygous T/T risk allele
carriers exhibit slightly reduced insulin release under both
basal and glucose-stimulated conditions. Moreover, a reduc-
tion in islet density is accompanied by an increased islet size
and, importantly, an apparent increase in the ratio of alpha to
beta cells in the islets. These observations call for further
mechanistic studies and the pTcf7l2 mouse strain may be a
useful tool for such endeavours.
Several questions remain to be answered: for example,
we are still at a loss as to how the appropriate type 2 diabetes
mouse model should be constructed. Whereas several
reports of increased TCF7L2 transcript expression in human
islets from patients with type 2 diabetes have emerged, this
does not necessarily translate to TCF7L2 protein produc-
tion. By contrast, islet TCF7L2 protein production has been
suggested to be reduced in type 2 diabetes [9]. Furthermore,
the isoform pattern in different tissues is beginning to un-
ravel [12, 17, 18] and needs to be determined according to
genotype. When effects on target specificity and down-
stream transcriptional activity have finally been determined
before and after onset of type 2 diabetes, there will be better
prospects for specific intervention.
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